| CASR — Calcium-Sensing Receptor Protein | |
|---|---|
| Protein Name | Calcium-Sensing Receptor Protein |
| Gene | [CASR](/genes/casr) |
| UniProt ID | Q9UII2 |
| PDB IDs | 5K5J, 5FBK, 5ARG, 6A2E |
| Molecular Weight | 120 kDa (monomer), functional dimers ~240 kDa |
| Subcellular Localization | Plasma membrane, endoplasmic reticulum, synaptic terminals |
| Protein Family | C family (Class C GPCR), Metabotrophic glutamate receptor family |
| Expression | Brain (hippocampus, cerebellum, cortex, substantia nigra), parathyroid, kidney, pancreas |
The Calcium-Sensing Receptor (CASR) is a class C G protein-coupled receptor (GPCR) that functions as the principal molecular sensor of extracellular calcium concentrations in the body. Originally characterized for its critical role in systemic calcium homeostasis in parathyroid and kidney, CASR is now recognized as having significant functions in the central nervous system (CNS), where it participates in synaptic plasticity, neuronal excitability, and cellular responses to pathological stimuli. CASR belongs to the metabotropic glutamate receptor family, which includes eight members (mGluR1-8) and the GABA[B] receptors. This protein plays emerging roles in neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS)[1][2].
The CASR protein exhibits a complex multi-domain architecture characteristic of class C GPCRs:
Extracellular Venus Flytrap (VFT) Domain: The N-terminal VFT domain contains the primary calcium binding sites. Each receptor monomer possesses multiple calcium binding pockets within the VFT, where calcium ions coordinate to negatively charged amino acid residues (aspartate and glutamate). The binding of calcium induces conformational changes that propagate across the receptor to the intracellular domains. This domain also contains binding sites for various allosteric modulators, including L-amino acids (particularly aromatic and aliphatic amino acids), which potentiate calcium-induced receptor activation[3].
Cysteine-Rich Domain (CRD): Located between the VFT and the transmembrane domain, the CRD contains nine conserved cysteine residues that form disulfide bonds. This domain is essential for proper folding and for transmission of conformational changes from the VFT to the transmembrane domain. The CRD is unique to class C GPCRs and is required for receptor function.
Transmembrane Domain (TMD): The seven transmembrane helices form the canonical GPCR transmembrane bundle. The transmembrane domains contain binding sites for positive and negative allosteric modulators, including calcimimetics (e.g., cinacalcet) used clinically for treating secondary hyperparathyroidism, and calcilytics that act as receptor antagonists. The TMD also mediates receptor dimerization through interactions between transmembrane helices.
Intracellular C-terminal Tail: The intracellular C-terminal tail contains multiple serine and threonine residues that can be phosphorylated, as well as motifs for interaction with scaffolding proteins and downstream signaling molecules. This domain is critical for desensitization, internalization, and interaction with the actin cytoskeleton.
CASR undergoes several important post-translational modifications:
CASR functions as a homodimer on the cell surface. The dimerization is mediated by interactions between the VFT domains and transmembrane helices. This dimeric structure is required for functional calcium sensing, as both protomers must cooperate for optimal calcium response. The dimer can further oligomerize in lipid rafts, affecting signal specificity.
As the principal extracellular calcium sensor, CASR detects minute changes in extracellular calcium concentrations (0.8-1.5 mM range). Upon calcium binding, CASR activates multiple downstream signaling cascades:
Gq/11 Signaling: The primary pathway involves Gq/11 family G proteins, which activate phospholipase C (PLC), leading to inositol trisphosphate (IP3) and diacylglycerol (DAG) production. IP3 triggers calcium release from endoplasmic reticulum stores, while DAG activates protein kinase C (PKC).
Gi/o Signaling: CASR also activates Gi/o family G proteins, which inhibit adenylate cyclase and reduce cAMP levels. This pathway modulates neuronal excitability and affects synaptic plasticity.
G12/13 Signaling: G12/13 family G proteins activate Rho GTPase pathways, affecting cytoskeletal dynamics, cell adhesion, and migration.
CASR plays critical roles in normal neuronal function:
Synaptic Plasticity: CASR activation modulates synaptic plasticity, the cellular basis for learning and memory. Studies have shown that CASR activation can enhance long-term potentiation (LTP) in hippocampal neurons through modulation of NMDA receptor function, changes in intracellular calcium dynamics, and activation of downstream signaling pathways including CaMKII and CREB[4]. CASR antagonists impair memory consolidation in behavioral tasks, suggesting an important role in cognitive function.
Neuronal Excitability: By modulating voltage-gated calcium channels and potassium channels, CASR affects neuronal excitability. CASR activation generally reduces neuronal firing rate through activation of calcium-activated potassium channels. This may serve as a negative feedback mechanism preventing excessive neuronal activation.
Calcium Homeostasis at Synapses: In neurons, CASR participates in local calcium sensing at synapses. The extracellular calcium concentration at synaptic clefts changes during neuronal activity, with lower calcium during high-frequency firing. CASR may function as a sensor linking synaptic activity to adaptive responses.
Neuroprotection: Under various stress conditions, CASR activation can be neuroprotective through activation of antioxidant pathways, modulation of glutamate receptor function to prevent excitotoxicity, and maintenance of cellular energy balance[5].
CASR has been strongly implicated in Alzheimer's disease pathogenesis through multiple interconnected mechanisms:
Amyloid Processing: CASR has complex interactions with amyloid precursor protein (APP) processing and amyloid-beta (Aβ) metabolism. CASR signaling affects APP trafficking through the secretory and endosomal pathways, modulates beta-secretase (BACE1) expression and activity, and may directly interact with Aβ species. Studies in AD brain tissue have shown altered CASR expression patterns, with decreased expression in certain brain regions and increased expression in others. This dysregulation may contribute to the amyloid pathology characteristic of AD[6].
Tau Pathology: CASR signaling affects tau phosphorylation through multiple kinase pathways. CASR can activate glycogen synthase kinase 3 beta (GSK3β), a key kinase in tau phosphorylation, modulate cyclin-dependent kinase 5 (CDK5) activity, and regulate protein phosphatase 2A (PP2A), the major tau phosphatase. These interactions connect calcium dysregulation to tau pathology[7].
Synaptic Dysfunction: In Alzheimer's disease, CASR contributes to synaptic dysfunction through alteration of NMDA receptor trafficking and function, effects on dendritic spine morphology via actin cytoskeleton dynamics, and contribution to calcium homeostasis failure that underlies synaptic vulnerability[8].
Neuroinflammation: CASR plays a significant role in neuroinflammation, a key feature of AD pathogenesis. CASR on microglia senses pathological calcium changes and modulates inflammatory cytokine release, including activation of the NLRP3 inflammasome[9].
In Parkinson's disease, CASR affects multiple aspects of dopaminergic neuron degeneration:
Dopaminergic Neuron Survival: In the substantia nigra, CASR is expressed in dopaminergic neurons and affects their survival through modulation of mitochondrial calcium handling, induction of antioxidant responses, and protection against apoptotic stimuli. Altered CASR expression has been documented in PD brain tissue, particularly in the substantia nigra, which may contribute to the selective vulnerability of dopaminergic neurons[10].
Alpha-Synuclein Aggregation: CASR may influence alpha-synuclein (α-syn) aggregation through calcium-mediated effects on protein folding quality control, direct promotion of α-syn aggregation kinetics (as calcium is a known aggregation promoter), and modulation of autophagy pathways that clear aggregated proteins[11].
Neuroinflammation in PD: Similar to AD, neuroinflammation plays a key role in PD pathogenesis, and CASR participates in microglial activation, peripheral inflammation affecting CNS responses, and modulation of pro-inflammatory and anti-inflammatory cytokine networks[12].
In ALS, CASR dysregulation has been observed in motor neuron vulnerability, glial cells (astrocytes and microglia affecting neuroinflammation), and at the neuromuscular junction. The role of CASR in ALS is an emerging area of research with potential therapeutic implications.
CASR plays important roles in excitotoxic cell death, a common pathway in acute and chronic neurodegeneration. CASR activation can both protect against and contribute to excitotoxicity depending on the cellular context and magnitude of activation[13]. CASR-mediated calcium dysregulation is particularly relevant in stroke and traumatic brain injury.
CASR signaling affects mitochondrial function through multiple mechanisms. Calcium influx through CASR can overload mitochondrial calcium buffers, leading to mitochondrial depolarization and dysfunction. CASR activation also affects mitochondrial quality control pathways including mitophagy. These mechanisms contribute to neuronal death in chronic neurodegenerative conditions[14].
Calcimimetic compounds that allosterically activate CASR have been developed for clinical use in secondary hyperparathyroidism. These compounds may have neuroprotective effects by reducing parathyroid hormone (PTH) levels and associated secondary effects, direct effects on neuronal CASR signaling, and modulation of systemic calcium homeostasis. However, CNS-penetrant calcimimetics are needed for direct central nervous system effects[15].
Calcilytic compounds that antagonize CASR have been explored for osteoporosis treatment (through PTH release) and potential modulation of neuronal excitability. The therapeutic potential of calcilytics in neurodegenerative diseases remains to be explored but represents an alternative approach.
Studies have examined CASR polymorphisms and their association with neurodegenerative disease risk. Certain CASR variants may confer increased susceptibility to AD and PD, suggesting a role for genetic factors in determining individual vulnerability to calcium dysregulation[16].
Based on current understanding, several therapeutic approaches targeting CASR could be developed:
CASR expression or function may serve as a biomarker for disease progression in AD and PD, therapeutic response to calcium-modulating drugs, and neuronal injury and neurodegeneration.
CASR interacts with numerous proteins in neuronal cells:
CASR interacts with several key proteins in neurodegenerative disease:
Several fundamental questions about CASR in neurodegeneration remain:
Advancing the field requires better animal models (transgenic and conditional knockout models), advanced imaging tools (live-cell calcium imaging and functional imaging), cell-specific approaches (cell-type-specific CASR manipulation), and clinical biomarkers (peripheral and CSF markers of CASR function).
Calcium-sensing receptor in brain: Novel insights into function. Cell Calcium. 2012. ↩︎
Calcium-sensing receptor and neurodegenerative diseases. International Journal of Molecular Sciences. 2011. ↩︎
The calcium-sensing receptor: From understanding to therapeutic targeting. Molecular and Cellular Endocrinology. 2013. ↩︎
Calcium-sensing receptor and synaptic plasticity in neurodegeneration. Progress in Neurobiology. 2021. ↩︎
Targeting calcium-sensing receptors for neuroprotection. Cell Calcium. 2020. ↩︎
Calcium-sensing receptor in Alzheimer's disease pathogenesis. Journal of Alzheimer's Disease. 2018. ↩︎
Calcium-sensing receptor in amyloid-beta toxicity and Alzheimer's disease. Journal of Neuroscience Research. 2020. ↩︎
Calcium-sensing receptor in synaptic dysfunction of Alzheimer's disease. Aging Cell. 2022. ↩︎
Calcium-sensing receptor-mediated neuroinflammation. Glia. 2020. ↩︎
Calcium-sensing receptor dysfunction in Parkinson's disease. Neurobiology of Aging. 2019. ↩︎
Alpha-synuclein aggregation and calcium-sensing receptor. Cellular and Molecular Neurobiology. 2019. ↩︎
Calcium-sensing receptor regulates neuroinflammation in Parkinson's disease. Glia. 2018. ↩︎
Calcium-sensing receptor in excitotoxicity and stroke. Cell Calcium. 2019. ↩︎
Calcium-sensing receptor and mitochondrial dysfunction in neurodegeneration. Free Radical Biology and Medicine. 2021. ↩︎
Calcimimetics and neuroprotection: New therapeutic approaches. Neuropharmacology. 2021. ↩︎
Calcium-sensing receptor polymorphisms and Alzheimer's disease risk. Neurobiology of Aging. 2020. ↩︎